

The Novel Psychoactive Substances Epidemic: a Scientometric Perspective

Michelle Jin Yee Neoh^a, Alessandro Carollo^b, Mengyu Lim^a, Ornella Corazza^{b,c}, Aurora Coppola^d, Gianluca Esposito^{b,*}

^a*Psychology Program, Nanyang Technological University, Singapore, 639818, Singapore*

^b*Department of Psychology and Cognitive Science, University of Trento, Rovereto, TN, 38068, Italy*

^c*School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom*

^d*Psychology Unit, Azienda Provinciale per i Servizi Sanitari, Trento, Italy, Rovereto, TN, 38068, Italy*

Abstract

The unprecedented proliferation of novel psychoactive substances (NPS) in the illicit drug market has been a public health concern since their emergence in the 2000s. Their consumption can pose a severe health risks as their mechanism of action is poorly understood and their level of toxicity is high mainly due to the diffusion of very potent synthetic cannabinoids and synthetic opioids. This study systemically analyses the evolution of the scientific literature on NPS to gain a better understanding of the areas of major research interests and how they interlink. Findings indicate that the published evidence covers clusters focused on classes of NPS that have received widespread media attention, such as mephedrone and fentanyl, and have largely been concerned with the pharmacological and the toxicological profiles of these substances. This scientometric perspective also provides greater insight into the knowledge gaps within this new and rapidly growing field of study and highlights the need for an interdisciplinary approach in tackling the NPS epidemic.

Keywords: document co-citation analysis, novel psychoactive substances, substance use, synthetic cannabinoids, synthetic opioids

*Correspondence: Corso Bettini 31, Rovereto, TN, 38068, Italy.

Email address: gianluca.esposito@unitn.it (Gianluca Esposito)

1 **1. Introduction**

2 In recent years, there has been an unprecedented proliferation of novel
3 psychoactive substances (NPS) in the drug market globally with 1124 sub-
4 stances being reported to the United Nations Office on Drugs and Crime by
5 December 2021 [1]. The term NPS is typically used to refer to substances
6 originally designed as legal alternatives to controlled substances, such as ana-
7 logues of existing controlled drugs and pharmaceutical products designed to
8 mimic their actions and effects [2, 3]. The emergence of NPS in the illicit
9 drug market poses a serious challenge for drug policy and public health. The
10 ease and speed with which NPS are continuously developed and reintroduced
11 in the market as analogues or derivatives with small chemical changes in or-
12 der to circumvent drug enforcement and legislation makes these substances
13 difficult to legally regulate and control. In addition, the potency, pharma-
14 cological effects and risk profiles of NPS are diverse and generally unknown,
15 where users are often misinformed and lack awareness of the contents of the
16 NPS they are consuming. The properties and long-term effects of NPS are
17 not well understood and few studies examining most of these new substances
18 have been published [4].

19
20 Adverse health effects including suicide and fatalities have been docu-
21 mented in association with and attributed to NPS use [5] and the most
22 frequent classes of NPS are associated with medical risks [6]. In an analysis
23 of hospital emergency data by the European Drug Emergencies Network, 9%
24 of all drug-related emergencies involved NPS [7]. Reports have also cited
25 correlations between NPS use and increased spread of diseases such as HIV
26 and hepatitis C [8]. Although case reports and case series form the bulk of
27 research informing our understanding of NPS, it is apparent that there are
28 significant health risks associated with NPS use.

29
30 Although the prevalence of NPS in the general population appears to be
31 low, their consumption among younger age groups is higher and warrants
32 concern. A systematic review found that most studies showed 3% or less
33 of adult populations reported recent use of NPS, typically in the past year,
34 compared to an estimated 1 in 10 young people [9]. Similarly, an estimated
35 1-8% of school students have used NPS at some point [10], indicating a wor-

36 rying trend of drug use among youth. However, it is important to note that
37 such self-report data on NPS use are most likely not an accurate representa-
38 tion of actual market penetration and user uptake of NPS due to the sheer
39 speed in which NPS are introduced to market as well as unwitting consumers.

40
41 The aim of this study is to identify the most relevant publications, the
42 nature of their inquiry and associate literature gaps in the field of NPS.
43 We conducted a document co-citation analysis (DCA) [11, 12] to analyse
44 references and the relevance of these publications in the existing literature
45 on NPS. By clustering publications according to common research domains,
46 articles with significant contributions to the literature can be identified while
47 highlighting the coverage and gaps in existing literature. The scientometric
48 results can illuminate research and identifying publication trends, the links
49 between different works and scientific fields involved in the exploration of
50 issues relating to NPS. The scientometric approach has been employed in
51 neuroscience [13] and digital psychology [14].

52 2. Material and Methods

53 Publications were downloaded from Scopus in accordance with the stan-
54 dard and established scientometric procedures [11]. We used the following
55 search string TITLE-ABS-KEY(“novel psychoactive substanc*” OR “new
56 psychoactive substanc*”) AND (LIMIT-TO (LANGUAGE , “English”))
57 and found a total of 2,365 documents published from 1 January 2010 to 13
58 June 2022. By limiting the search to publications in English, the analysis
59 will be built on international scientific literature in the field, allowing for a
60 more standardised and rigorous examination of existing work [15].

61 2.1. Data import on CiteSpace

62 Scientometric analysis was conducted using CiteSpace software (Version
63 6.1.R2) and the articles downloaded from Scopus were imported into the
64 software. 106,911 of a total of 111,855 references (95.58%) cited by the 2,365
65 articles were valid (Figure 1). A “valid” reference is one that contains seven
66 key pieces of information: author, year of publication, title, source, volume,
67 pages and DOI [11]. Due to irregularities in the citation format, a number
68 of references were considered invalid. Negligible losses in references (1-5%)
69 commonly occur during the data import to the CiteSpace software [16]. The

70 CiteSpace function (Remove Alias) was turned ON to eliminate repeated or
71 identical entries.




Figure 1: PRISMA flowchart for search criteria and reference eligibility

72 2.2. Document Co-Citation Analysis (DCA) and Optimisation of Parameters

73 DCA was conducted to determine the main research domains in NPS
74 literature. DCA is based on the frequency with which two or more papers
75 are cited together in source articles [17]. The assumption is that frequent
76 co-citations among articles reflect common research trends and intellectual
77 domains in the literature [12, 18]. The network resulting from the DCA is
78 composed of documents frequently cited together along with the documents
79 that cite them (i.e. articles downloaded from Scopus).

80 DCA parameters were optimised in order to obtain a balanced network
81 of documents. Several DCAs were computed and compared, each with a
82 different setting for one of three node selection criteria; g-index, TOP N ,
83 TOP $N\%$, as done in [13, 15, 18, 19, 14, 20]. The node selection criteria
84 are *a priori* settings that define the criterion used for selecting articles to be

85 included in the network, and consequently, determine the final network of
86 articles being generated. The g-index is a measure of the citation scores of
87 an author's top publications [21, 22]. It represents the largest number that
88 equals the average number of citations of the most highly cited g publications
89 [16]. TOP N and TOP $N\%$ are criteria used to select N and $N\%$ most
90 cited within a time slice (1 year was used in this study) as network nodes
91 respectively [11].

92 In order to generate the final optimal network, node selection criteria were
93 varied together with their scale factor values, which refer to the chosen nu-
94 meric values used as thresholds for the respective node selection criteria [14].
95 Specifically, DCAs with the following node selection criteria were compared:
96 g-index with scale factor k set at 10, 15, 25, 50, TOP N with scale factor N
97 set at 25, 50 and TOP $N\%$ with scale factor N set at 10. To determine the
98 node selection criteria and scale factor to use for the generation of the final
99 network, the overall effects on the structural metrics of the generated net-
100 work, the number of nodes included and clusters identified were compared.
101 After comparison of these metrics, TOP N with N at 25 was the parameter
102 which was used to generate the final network of articles.

103 2.3. Metrics

104 Structural and temporal metrics are used in describing CiteSpace results.
105 Structural metrics consist of (i) *modularity-Q*, (ii) *silhouette scores* and (iii)
106 *betweenness centrality*. Modularity-Q values range from 0 to 1 and indicates
107 the degree to which the network can be decomposed into single groups of
108 nodes, which are referred to as modules or clusters [23]. High modularity-
109 Q values indicate a well-structured network [12]. Silhouette scores are a
110 measure of inner consistency - cohesion and separation - of the modules [24].
111 Silhouette scores vary from -1 to +1, where higher values represent high
112 separation from other modules and internal consistency [25]. Betweenness
113 centrality represents the degree to which a node connects an arbitrary pair of
114 nodes in the network [11, 26]. Betweenness centrality values range from 0 to
115 1, where groundbreaking and revolutionary works in the scientific literature
116 typically score higher [27].

117 Temporal metrics consist of (i) *citation burstness* and (ii) *sigma*. The
118 Kleinberg's algorithm [28] is used to calculate citation burstness, which in-
119 dicates a sudden increase in the number of citations of an article in a given
120 time frame [29]. Sigma is calculated with the equation $(\text{centrality} + 1)^{\text{burstness}}$

121 and indicates the novelty of a document and influence on the overall network
122 [30].

123 The overall configuration of the generated network and identified clusters
124 of references were examined with modularity-Q and silhouette scores. The
125 attributes of single nodes in the network were examined using betweenness
126 centrality and the temporal metrics.

127 3. Results

128 3.1. Structural metrics

129 The final optimised network obtained from the DCA consisted of 317
130 nodes and 1,327 links, indicating an average of 4.15 connections with other
131 references for each node (Figure 2). The network had a modularity-Q index of
132 0.6181 and a mean silhouette score of 0.8445, indicating medium divisibility
133 of the network into clusters that are highly homogenous.




Figure 2: Network of publications generated through the document co-citation analysis (DCA). The major clusters are grouped by colour.

134 3.2. Citation burstness

135 A total of 64 documents were found to exhibit a citation burstness (Table
136 1). 20 of these documents belong to cluster #0, 13 to cluster #1, 16 to cluster
137 #2, 4 to cluster #3, 3 to cluster #4, 1 to cluster #5, 4 to cluster #6 and
138 1 to cluster #9. The article with the highest burst strength was authored
139 by Honderbrink et al. in 2015 [31] with a score of 12.43. The burst began
140 in 2017 and ended in 2019. The article with the longest burst duration was

141 authored by Castaneto et al. in 2014 [32] with a burst duration of 5 years
 142 from 2017 to 2022. The article with the highest sigma value was authored
 143 by Hermanns-clausen in 2013 [33] with a sigma value of 2.44.

Table 1: Top 15 publications in terms of burst strength.

Reference	Burst	Year	Start of burstness	End of burstness	Burst duration	Centrality	Sigma
Hondebrink et al. [31]	12.43	2015	2017	2019	2	0.01	1.10
Armenian et al. [34]	11.68	2018	2019	2022	3	0.02	1.19
Peacock et al. [9]	10.97	2019	2020	2022	2	0.01	1.08
Brandt et al. [35]	10.93	2014	2016	2017	1	0.00	1.00
Rickli et al. [36]	10.58	2015	2017	2018	1	0.00	1.04
Morris et al. [37]	10.07	2014	2017	2018	1	0.05	1.67
Measham et al. [38]	9.46	2011	2012	2014	2	0.07	1.90
Hermanns-clausen et al. [33]	9.44	2013	2014	2017	3	0.01	2.44
Kraemer et al. [39]	8.62	2019	2020	2022	2	0.02	1.17
Seely et al. [40]	8.51	2012	2015	2018	3	0.04	1.41
Richter et al. [41]	8.26	2017	2019	2020	1	0.00	1.01
Baumann et al. [42]	7.92	2012	2016	2017	1	0.01	1.09
Prosser et al. [43]	7.81	2012	2016	2017	1	0.17	3.50
Majchrzak et al. [44]	7.68	2018	2020	2022	2	0.01	1.12
Favretto et al. [45]	7.55	2013	2015	2017	2	0.01	1.10

144 3.3. Thematic clusters

145 Ten major clusters were identified (Figure 2, Table 2). The largest cluster
 146 #0 consisted of 59 nodes and had a silhouette score of 0.716, where the
 147 constituent references were published in 2019 on average. The cluster was
 148 labelled “Mechanisms of NPS action”. Second, cluster #1 consisted of 56
 149 nodes and had a silhouette score of 0.84, where the constituent references
 150 were published in 2012 on average. The cluster was labelled “Availability and
 151 use of NPS”. Third, cluster #2 consisted of 49 nodes and had a silhouette
 152 score of 0.809, where the constituent references were published in 2014 on
 153 average. The cluster was labelled “Neuropharmacology of NPS”.

Table 2: Metrics of the 10 clusters identified with the DCA. Log-likelihood Ratio (LLR) labels are automatically generated by the software.

Cluster ID	Size	Silhouette	Mean year	LLR label	Proposed label
0	59	0.716	2019	Synthetic cannabinoid	Mechanisms of NPS action
1	56	0.840	2012	Psychoactive substance	Availability and use of NPS
2	49	0.809	2014	Acute recreational drug toxicity	Neuropharmacology of NPS
3	34	0.820	2016	Strida project	Intoxication profile and detection of NPS use
4	26	0.994	2020	New synthetic opioid	New synthetic opioids
5	18	0.992	2012	Legal consequence	Legal aspects of NPS use
6	13	0.928	2017	Synthetic cannabinoid	Synthetic cannabinoids
8	8	0.984	2014	Rat urine	Metabolite profiles for drug screening
9	6	1.00	2013	Mapping project	NPS and the Internet
10	6	0.967	2015	Emerging epidemic	NPS as a New Public Health Problem

154 4. Discussion

155 In this section, we will discuss each cluster in greater detail in chrono-
156 logical order, by the average year of publication of the cluster. Each cluster
157 will be analysed in terms of both the citing articles and the cited references.
158 The main citing articles for each cluster will be highlighted, together with
159 its coverage and Global Citing Score (GCS). Coverage refers to the number
160 of articles in the cluster that were cited by the citing article and GCS refers
161 to the total number of citations received by a paper as indexed on Scopus.

162 4.1. Cluster #5: Legal aspects of NPS

163 The major citing articles in Cluster #5 were authored by Bilinski et al.
164 [46] with a coverage of 14 articles and GCS of 6, and B McNabb et al. [47]
165 with a coverage of 11 articles and GCS of 11. Cluster #5 appears to be
166 one of the earlier groups of work investigating NPS emerging on the drug
167 market, their effects and their legal status, as seen from the mean year of
168 publication (2012) and a significant number of cited references conducted in
169 animal models prior to 2010 [48, 49, 50, 51, 52]. The primary theme of this
170 cluster appears to be legal concerns of NPS use following their entrance into
171 the market, where the citing articles focused on the legality of designer drugs
172 touted as “legal” in the drug market [46, 47]. Accordingly, there were also
173 cited references looking into the legal aspects of NPS use [53, 54].

174 4.2. Cluster #1: Availability and use of NPS

175 The major citing articles in Cluster #1 were authored by Smith and
176 Garlich [55] with a coverage of 21 articles and GCS of 14, Wood and Dargan
177 [56] with a coverage of 16 articles and GCS of 7, and Wood and Dargan [57]
178 with a coverage of 14 articles and GCS of 54. Cluster #1 appears to be a
179 body of work that emerged in response to the series of bans on mephedrone
180 as well as other cathinones across multiple countries across the world in
181 2010, as evidenced by the mean year of publication (2012). The focus of
182 both citing articles and the cited references appeared to be the same, which
183 primarily revolved about the effects, prevalence and use of mephedrone and
184 other cathinones. A significant number of cited references examined their
185 use [38, 58, 59] and continued presence in the composition of existing drug
186 products available in the market [60, 35] despite their legal status, as well
187 as their effects (e.g. [61, 59, 62, 63]). This was also the case for many of
188 the citing articles which also looked at the effects of mephedrone and other
189 cathinones [57, 64, 56, 65].

190 *4.3. Cluster #9: NPS and the Internet*

191 The major citing articles in Cluster #9 were authored by Deluca et al. [66]
192 with a coverage of 3 articles and GCS of 139, Cinosi et al. [67] with a coverage
193 of 2 articles and GCS of 99, and Corazza et al. [68] with a coverage of 2 articles
194 and GCS of 52. The main theme of Cluster #9 is the role of the Internet as
195 a source for information on NPS as well as a virtual marketplace for NPS.
196 It is clear from the cited articles that the availability of NPS through online
197 channels is a key concern, especially since consumer reach and engagement
198 on the Internet is unrivalled in comparison to a brick-and-mortar store, as
199 well as the information on NPS available on the Internet (e.g. [69, 70, 71,
200 72]). Targeting the Internet through researching and designing web-based
201 interventions such as web monitoring and information dissemination is thus
202 a recommendation and/or central focus of the citing articles in Cluster #9
203 (e.g. [66, 68]). Research in Cluster #9 highlights the information war on the
204 Internet as a key aspect of the NPS crisis and the importance of developing
205 information and communication technology interventions.

206 *4.4. Cluster #8: Metabolite profiles for drug screening*

207 The two major citing articles in Cluster #8 were authored by Welter et al.
208 [73] with a coverage of 8 articles and GCS of 25 and Welter et al. [74] with a
209 coverage of 72 articles and GCS of 6. Both of these citing articles investigated
210 methods for detecting of designer drugs through screening the metabolic
211 products present in rat urine by applying gas chromatography-mass spec-
212 troscopy and/or liquid chromatography methods. This strongly suggests the
213 cluster is geared towards the application of these chemical methods to NPS
214 detection. Majority of the cited articles also report the results of applying
215 these methods to detect drug metabolites in urine (e.g. [75, 76, 77, 78, 79]).

216 *4.5. Cluster #2: Neuropharmacology of NPS*

217 The major citing articles in Cluster #2 were authored by Zawilska and
218 Andrzejczak [80] with a coverage of 10 articles and GCS of 120, Papaseit et al.
219 [81] with a coverage of 10 articles and GCS of 20, and [82] with a coverage
220 of 10 articles and GCS of 88, which were all reviews on the pharmacology
221 of NPS use. The cluster is centred in elucidating the pharmacology of the
222 various classes of NPS, which the citing articles covered from cathinones
223 (e.g. [83, 84]), cannabinoids (e.g. [85]), hallucinogens [86] and stimulants
224 [87]. The same theme is reflected in the cited articles, which were mostly
225 concerned with the toxicological findings from NPS use [33, 88, 43, 89, 90].

226 Hence, Cluster #2 appears to be a body of work relating pharmacological
227 properties of NPS to their toxicity and risk of fatality.

228 *4.6. Cluster #10: NPS as a New Public Health Problem*

229 The major citing articles in Cluster #10 were authored by Zawilska and
230 Andrzejczak [80] with a coverage of 4 articles and GCS of 36, Karila et al.
231 [91] with a coverage of 3 articles and GCS of 129, and Rickli et al. [36] with
232 a coverage of 3 articles and GCS of 129. The focus of these reviews aims to
233 consolidate information on properties of NPS in relation to their propensity
234 as a public health threat by presenting clinical data. The findings in the
235 cited references also presents clinical data [92], including psychosis [93].

236 *4.7. Cluster #3: Intoxication profile of NPS use*

237 The major citing articles in Cluster #3 were authored by Schifano et al.
238 [94] with a coverage of 7 articles and GCS of 178, Salomone [95] with a cov-
239 erage of 7 articles and GCS of 85, and Castaneto et al. [96] with a coverage
240 of 7 articles and GCS of 4, which were all reviews on the pharmacology of
241 NPS use. The cluster is composed of a group of work collecting data on
242 the intoxication profiles of NPS users (e.g. [97, 98, 99, 100, 101]). Notably,
243 a significant number of the citing articles analysed data from the STRIDA
244 project in Sweden, which monitored occurrences and health hazards of NPS
245 and includes information from about 2,600 cases of suspected NPS intoxica-
246 tions across the period of 2010-2016 [102, 103, 104, 105, 106, 107]. Similarly,
247 the cited references were also research on intoxication profiles and fatality
248 from NPS use (e.g. [108, 109, 110, 111, 112, 113, 114, 115]). The size of the
249 cluster alludes to the public health threat that NPS use poses, as well as the
250 importance of the field of emergency medicine in monitoring adverse events
251 relating to drug use which can provide much needed data on the toxicological
252 and risk profile of NPS use.

253 *4.8. Cluster #6: Synthetic cannabinoids*

254 The major citing articles in Cluster #6 were authored by Cannaert et al.
255 [116] with a coverage of 5 articles and GCS of 22, Ametovski et al. [117] with
256 a coverage of 5 articles and GCS of 5, and [118] with a coverage of 4 articles
257 and GCS of 18. Considering that marijuana - which contains cannabis - is
258 one of the most commonly use drugs in the world [119], it is not surprising
259 that synthetic cannabinoids gained popularity as a “legal” alternative in
260 countries - “Spice” being an example of a brand name cannabinoid drug

261 - where cannabis is controlled. Hence, this cluster of work examining the
262 effects of the recreational use of these synthetic cannabinoids appears to be in
263 response to their widespread use and market penetration in the recreational
264 drug market, especially considering its mean year of publication in 2017,
265 which was around the time period when cannabis began to be legalised for
266 recreational use and sale as a consumer product across a number of countries
267 such as Canada and the USA. The citing articles include research into the
268 pharmacology [120, 121, 122, 123], toxicology [124, 125, 126, 127] as well
269 as a number of articles pointing towards the sheer volume and continued
270 emergence of variations of synthetic cannabinoids [118, 128, 129]. Similarly,
271 a bulk of the cited references also focus mainly on synthetic cannabinoids
272 and their fatalities associated with their use [32, 130, 131, 132].

273 *4.9. Cluster #0: Mechanisms of NPS action*

274 The major citing articles in Cluster #0 were authored by Miliano et al.
275 [82] with a coverage of 13 articles and GCS of 88, Rudin et al. [133] with a
276 coverage of 12 articles and GCS of 9, and Ellefsen et al. [83] with a coverage
277 of 11 articles and GCS of 45, which were all reviews on the pharmacologi-
278 cal effects of NPS use. Firstly, many of the cited references in the cluster
279 discussed fatalities from NPS use (e.g. [31, 39, 134, 135]), indicating that
280 research on NPS is driven towards characterising the risk profile of NPS use
281 in terms of clinical outcomes and fatalities. Secondly, each of the major
282 citing articles were focused on different classes of NPS; Miliano et al. [82]
283 focused on cannabimimetics and amphetamine stimulants, Rudin et al. [133]
284 on stimulant and psychedelic NPS and Ellefsen et al. [83] on synthetic cathi-
285 nones. This highlights the diversity of NPS classes available, which poses
286 an immense challenge to the scientific community as evidenced by the con-
287 stant refrain of a lack of understanding of these mechanisms in many citing
288 articles. A tremendous effort is required in organising and conducting re-
289 search into understanding the drug action and effects of the different classes
290 of NPS, as seen from the size of this cluster. A defining characteristic of the
291 NPS phenomenon, the rapid development of NPS entering the drug market
292 suggests the continual need for research to update the scientific understand-
293 ing of the mechanisms of drug action, which is suggested by the relatively
294 recent mean year of publication (2019). Many of the references being cited
295 were also investigating the pharmacological actions and toxicity of NPS (e.g.
296 [36, 41, 136, 137, 138, 139]), further highlighting the need to constantly build

297 onto existing scientific knowledge because of the sheer speed of NPS varia-
298 tions being introduced in the market.

299 *4.10. Cluster #4: New synthetic opioids*

300 The major citing articles in Cluster #4 were authored by Vandeputte
301 et al. [140] with a coverage of 7 articles and GCS of 1, Vandeputte et al.
302 [141] with a coverage of 7 articles and GCS of 3, and [142] with a coverage of
303 7 articles and GCS of 10. Given its recent mean year of publication (2020),
304 the cluster is very likely to be a group of work in response to rising use of
305 synthetic opioids globally. While the opioid crisis is not a new phenomenon, a
306 spotlight has been thrown onto synthetic opioid use in the wake of the recent
307 surge in opioid overdose deaths in the US - an opioid overdose epidemic driven
308 by synthetic opioids, fentanyl and its derivatives in particular [143, 144, 145].
309 The cited reference with the highest burst strengths in this cluster focuses
310 on fentanyl and other novel synthetic opioids [34, 146, 147], supporting this
311 notion. Many citing articles were concerned with opioid-related deaths [39,
312 148, 149, 150] and a significant number of articles pointed towards the rapidly
313 surging numbers globally and its implications on public health [151, 152, 153].

314 *4.11. Limitations*

315 There are a number of limitations of the scientometric approach. The
316 DCA is based on the quantity of citations and co-citation patterns in the
317 retrieved references and does not provide a qualitative perspective for these
318 citation patterns per se. Hence, the rationale for the cited references are not
319 immediately clear from the scientometric analysis.

320 **5. Conclusions**

321 The NPS phenomenon is a major cause for concern in countries across
322 the globe and is a war on drugs fought on many fronts, as evidenced by the
323 diversity of scientific fields represented in the network of articles derived from
324 the DCA. Given the challenges that NPS pose in terms of drug monitoring,
325 surveillance, control and public health responses, understanding the scientific
326 literature and disciplines involved in research on NPS is a valuable contribu-
327 tion to the field which can be harnessed in supporting drug policy and public
328 health response. Such an analysis can highlight the research gaps in NPS
329 to direct attention to and facilitating interdisciplinary research based on the
330 research domains and links identified. In addition, producers of NPS often

331 mine knowledge from scientific journals and an understanding of the infor-
332 mation that is available can be useful in targeting and informing drug policy.
333 Thus, drug policy, monitoring and control can benefit from coordinated, in-
334 terdisciplinary efforts to inform and develop a multi-pronged approach to the
335 NPS crisis in order to safeguard public health.

336 **Conflict of interests**

337 The authors declare no conflict of interest.

338 **References**

- 339 [1] U. N. O. on Drugs, Crime, Unodc early warning advisory on new
340 psychoactive substances, 2021. URL: [https://www.unodc.org/LSS/
341 Page/NPS](https://www.unodc.org/LSS/Page/NPS).
- 342 [2] C. Soussan, A. Kjellgren, The users of novel psychoactive substances:
343 online survey about their characteristics, attitudes and motivations,
344 *International Journal of Drug Policy* 32 (2016) 77–84.
- 345 [3] A. Batisse, C. Eiden, H. Peyriere, S. Djeddar, et al., Use of new psy-
346 choactive substances to mimic prescription drugs: The trend in france,
347 *Neurotoxicology* 79 (2020) 20–24.
- 348 [4] C. D. Smith, S. Robert, ‘designer drugs’: update on the management of
349 novel psychoactive substance misuse in the acute care setting, *Clinical
350 medicine* 14 (2014) 409.
- 351 [5] C. D. Smith, M. Williams, M. Shaikh, Novel psychoactive substances:
352 a novel clinical challenge, *Case Reports* 2013 (2013) bcr2013200663.
- 353 [6] N. Scherbaum, F. Schifano, U. Bonnet, New psychoactive substances
354 (nps)—a challenge for the addiction treatment services, *Pharmacopsy-
355 chiatry* 50 (2017) 116–122.
- 356 [7] P. O. of the European Union, M. Evans-Brown, A. Gallegos, W. Fran-
357 cis, R. Christie, A. Cunningham, J. Sekula, A. Almeida, R. Sedefov,
358 Publications Office, 2015.
- 359 [8] M. Evans-Brown, R. Sedefov, New psychoactive substances: driving
360 greater complexity into the drug problem, *Addiction* 112 (2017) 36–38.

- 361 [9] A. Peacock, R. Bruno, N. Gisev, L. Degenhardt, W. Hall, R. Sedefov,
362 J. White, K. V. Thomas, M. Farrell, P. Griffiths, New psychoactive
363 substances: challenges for drug surveillance, control, and public health
364 responses, *The Lancet* 394 (2019) 1668–1684.
- 365 [10] L. Kraus, A. Nociar, ESPAD report 2015: results from the European
366 school survey project on alcohol and other drugs, European Monitoring
367 Centre for Drugs and Drug Addiction, 2016.
- 368 [11] C. Chen, *The citespace manual*, College of Computing and Informatics
369 1 (2014) 1–84.
- 370 [12] C. Chen, F. Ibekwe-SanJuan, J. Hou, The structure and dynamics of
371 cocitation clusters: A multiple-perspective cocitation analysis, *Journal*
372 *of the American Society for information Science and Technology* 61
373 (2010) 1386–1409.
- 374 [13] A. Carollo, J. P. M. Balagtas, M. J.-Y. Neoh, G. Esposito, A sciento-
375 metric approach to review the role of the medial preoptic area (mpoa)
376 in parental behavior, *Brain Sciences* 11 (2021) 393.
- 377 [14] I. Cataldo, A. A. Lieu, A. Carollo, M. H. Bornstein, G. Gabrieli, A. Lee,
378 G. Esposito, From the cradle to the web: The growth of “sharent-
379 ing”—a scientometric perspective, *Human Behavior and Emerging*
380 *Technologies* 2022 (2022).
- 381 [15] A. Carollo, A. Bonassi, M. Lim, G. Gabrieli, P. Setoh, D. Dimitriou,
382 V. Aryadoust, G. Esposito, Developmental disabilities across the world:
383 A scientometric review from 1936 to 2020, *Research in Developmental*
384 *Disabilities* 117 (2021) 104031.
- 385 [16] C. Chen, *CiteSpace: a practical guide for mapping scientific literature*,
386 Nova Science Publishers Hauppauge, NY, USA, 2016.
- 387 [17] H. Small, Co-citation context analysis and the structure of paradigms,
388 *Journal of documentation* (1980).
- 389 [18] A. Carollo, M. Lim, V. Aryadoust, G. Esposito, Interpersonal syn-
390 chrony in the context of caregiver-child interactions: a document co-
391 citation analysis, *Frontiers in Psychology* (2021) 2977.

- 392 [19] A. Carollo, S. Fong, G. Gabrieli, C. Mulatti, G. Esposito, To wine or
393 not to wine? a scientometric approach to 65+ years of wine preference
394 and selection studies, *British Food Journal* (2022).
- 395 [20] M. Lim, A. Carollo, D. Dimitriou, G. Esposito, Recent developments
396 in autism genetic research: A scientometric review from 2018 to 2022,
397 *Genes* 13 (2022) 1646.
- 398 [21] L. Egghe, Theory and practise of the g-index, *Scientometrics* 69 (2006)
399 131–152.
- 400 [22] S. Alonso, F. J. Cabrerizo, E. Herrera-Viedma, F. Herrera, h-index:
401 A review focused in its variants, computation and standardization for
402 different scientific fields, *Journal of informetrics* 3 (2009) 273–289.
- 403 [23] M. E. Newman, Modularity and community structure in networks,
404 *Proceedings of the national academy of sciences* 103 (2006) 8577–8582.
- 405 [24] P. J. Rousseeuw, Silhouettes: a graphical aid to the interpretation and
406 validation of cluster analysis, *Journal of computational and applied
407 mathematics* 20 (1987) 53–65.
- 408 [25] V. Aryadoust, B. H. Ang, Exploring the frontiers of eye tracking re-
409 search in language studies: a novel co-citation scientometric review,
410 *Computer Assisted Language Learning* 34 (2021) 898–933.
- 411 [26] L. C. Freeman, A set of measures of centrality based on betweenness,
412 *Sociometry* (1977) 35–41.
- 413 [27] V. Aryadoust, H. A. H. Tan, L. Y. Ng, A scientometric review of
414 rasch measurement: The rise and progress of a specialty, *Frontiers in
415 psychology* (2019) 2197.
- 416 [28] J. Kleinberg, Bursty and hierarchical structure in streams, *Data mining
417 and knowledge discovery* 7 (2003) 373–397.
- 418 [29] C. Chen, Science mapping: a systematic review of the literature, *Jour-
419 nal of data and information science* 2 (2017) 1–40.
- 420 [30] C. Chen, Y. Chen, M. Horowitz, H. Hou, Z. Liu, D. Pellegrino, To-
421 wards an explanatory and computational theory of scientific discovery,
422 *Journal of Informetrics* 3 (2009) 191–209.

- 423 [31] L. Hondebrink, J. J. Nugteren-van Lonkhuyzen, D. Van Der Gouwe,
424 T. M. Brunt, Monitoring new psychoactive substances (nps) in the
425 netherlands: data from the drug market and the poisons information
426 centre, *Drug and alcohol dependence* 147 (2015) 109–115.
- 427 [32] M. S. Castaneto, D. A. Gorelick, N. A. Desrosiers, R. L. Hartman,
428 S. Pirard, M. A. Huestis, Synthetic cannabinoids: epidemiology, phar-
429 macodynamics, and clinical implications, *Drug and alcohol dependence*
430 144 (2014) 12–41.
- 431 [33] M. Hermanns-Clausen, S. Kneisel, B. Szabo, V. Auwärter, Acute toxic-
432 ity due to the confirmed consumption of synthetic cannabinoids: clin-
433 ical and laboratory findings, *Addiction* 108 (2013) 534–544.
- 434 [34] P. Armenian, K. T. Vo, J. Barr-Walker, K. L. Lynch, Fentanyl, fen-
435 tanyl analogs and novel synthetic opioids: a comprehensive review,
436 *Neuropharmacology* 134 (2018) 121–132.
- 437 [35] S. D. Brandt, L. A. King, M. Evans-Brown, The new drug phenomenon,
438 2014.
- 439 [36] A. Rickli, M. C. Hoener, M. E. Liechti, Monoamine transporter and
440 receptor interaction profiles of novel psychoactive substances: para-
441 halogenated amphetamines and pyrovalerone cathinones, *European*
442 *Neuropsychopharmacology* 25 (2015) 365–376.
- 443 [37] H. Morris, J. Wallach, From pcp to mxe: a comprehensive review of
444 the non-medical use of dissociative drugs, *Drug testing and analysis* 6
445 (2014) 614–632.
- 446 [38] F. Measham, D. M. Wood, P. I. Dargan, K. Moore, The rise in legal
447 highs: prevalence and patterns in the use of illegal drugs and first-
448 and second-generation “legal highs” in south london gay dance clubs,
449 *Journal of Substance Use* 16 (2011) 263–272.
- 450 [39] M. Kraemer, A. Boehmer, B. Madea, A. Maas, Death cases involv-
451 ing certain new psychoactive substances: a review of the literature,
452 *Forensic science international* 298 (2019) 186–267.

- 453 [40] K. A. Seely, J. Lapoint, J. H. Moran, L. Fattore, Spice drugs are more
454 than harmless herbal blends: a review of the pharmacology and toxicol-
455 ogy of synthetic cannabinoids, *Progress in Neuro-psychopharmacology*
456 and biological psychiatry 39 (2012) 234–243.
- 457 [41] L. H. Richter, H. H. Maurer, M. R. Meyer, New psychoactive sub-
458 stances: studies on the metabolism of xlr-11, ab-pinaca, fub-pb-22,
459 4-methoxy- α -pvp, 25-i-nbome, and meclonazepam using human liver
460 preparations in comparison to primary human hepatocytes, and hu-
461 man urine, *Toxicology Letters* 280 (2017) 142–150.
- 462 [42] M. H. Baumann, M. A. Ayestas, J. S. Partilla, J. R. Sink, A. T.
463 Shulgin, P. F. Daley, S. D. Brandt, R. B. Rothman, A. E. Ruoho,
464 N. V. Cozzi, The designer methcathinone analogs, mephedrone and
465 methylone, are substrates for monoamine transporters in brain tissue,
466 *Neuropsychopharmacology* 37 (2012) 1192–1203.
- 467 [43] J. M. Prosser, L. S. Nelson, The toxicology of bath salts: a review of
468 synthetic cathinones, *Journal of Medical Toxicology* 8 (2012) 33–42.
- 469 [44] M. Majchrzak, R. Celiński, P. Kuś, T. Kowalska, M. Sajewicz, The
470 newest cathinone derivatives as designer drugs: an analytical and tox-
471 icological review, *Forensic toxicology* 36 (2018) 33–50.
- 472 [45] D. Favretto, J. P. Pascali, F. Tagliaro, New challenges and innovation
473 in forensic toxicology: focus on the “new psychoactive substances”,
474 *Journal of chromatography A* 1287 (2013) 84–95.
- 475 [46] P. Bilinski, P. Holownia, L. Kapka-Skrzypczak, A. Wojtyła, Designer
476 drug (dd) abuse in poland; a review of the psychoactive and toxic prop-
477 erties of substances found from seizures of illegal drug products and the
478 legal consequences thereof. part ii—piperazines/piperidines, phenylethy-
479 lamines, tryptamines and miscellaneous ‘others’, *Annals of Agricultural*
480 and *Environmental Medicine* 19 (2012).
- 481 [47] C. B McNabb, B. R Russell, D. Caprioli, D. J Nutt, S. Gibbons,
482 J. W Dalley, Single chemical entity legal highs: assessing the risk
483 for long term harm, *Current Drug Abuse Reviews* 5 (2012) 304–319.

- 484 [48] R. Nonaka, F. Nagai, A. Ogata, K. Satoh, In vitro screening of psy-
485 choactive drugs by [³⁵S] gtpγs binding in rat brain membranes, Bio-
486 logical and Pharmaceutical Bulletin 30 (2007) 2328–2333.
- 487 [49] F. Nagai, R. Nonaka, K. S. H. Kamimura, The effects of non-medically
488 used psychoactive drugs on monoamine neurotransmission in rat brain,
489 European journal of pharmacology 559 (2007) 132–137.
- 490 [50] W. E. Fantegrossi, G. Winger, J. Woods, W. Woolverton, A. Coop, Re-
491 inforcing and discriminative stimulus effects of 1-benzylpiperazine and
492 trifluoromethylphenylpiperazine in rhesus monkeys, Drug and alcohol
493 dependence 77 (2005) 161–168.
- 494 [51] K. M. Wilcox, H. L. Kimmel, K. P. Lindsey, J. R. Votaw, M. M. Good-
495 man, L. L. Howell, In vivo comparison of the reinforcing and dopamine
496 transporter effects of local anesthetics in rhesus monkeys, Synapse 58
497 (2005) 220–228.
- 498 [52] M. H. Baumann, R. D. Clark, A. G. Budzynski, J. S. Partilla, B. E.
499 Blough, R. B. Rothman, Effects of “legal x” piperazine analogs on
500 dopamine and serotonin release in rat brain, Annals of the New York
501 Academy of Sciences 1025 (2004) 189–197.
- 502 [53] S. Davies, D. M. Wood, G. Smith, J. Button, J. Ramsey, R. Archer,
503 D. W. Holt, P. I. Dargan, Purchasing ‘legal highs’ on the internet—is
504 there consistency in what you get?, QJM: An International Journal of
505 Medicine 103 (2010) 489–493.
- 506 [54] L. Kapka-Skrzypczak, P. Kulpa, K. Sawicki, M. Cyranka, A. Wojtyła,
507 M. Kruszewski, Legal highs-legal aspects and legislative solutions, An-
508 nals of Agricultural and Environmental Medicine 18 (2011).
- 509 [55] S. W. Smith, F. M. Garlich, Availability and supply of novel psychoac-
510 tive substances, in: Novel psychoactive substances, Elsevier, 2013, pp.
511 55–77.
- 512 [56] D. M. Wood, P. I. Dargan, Mephedrone, in: Novel psychoactive sub-
513 stances, Elsevier, 2013, pp. 211–231.

- 514 [57] D. M. Wood, P. I. Dargan, Novel psychoactive substances: how to un-
515 derstand the acute toxicity associated with the use of these substances,
516 *Therapeutic drug monitoring* 34 (2012) 363–367.
- 517 [58] D. Wood, L. Hunter, F. Measham, P. Dargan, Limited use of novel
518 psychoactive substances in south london nightclubs, *QJM: An inter-
519 national journal of medicine* 105 (2012) 959–964.
- 520 [59] P. Dargan, S. Albert, D. Wood, Mephedrone use and associated ad-
521 verse effects in school and college/university students before the uk
522 legislation change, *QJM: An International Journal of Medicine* 103
523 (2010) 875–879.
- 524 [60] J. Ramsey, P. Dargan, M. Smyllie, S. Davies, J. Button, D. Holt,
525 D. Wood, Buying ‘legal’ recreational drugs does not mean that you
526 are not breaking the law, *QJM: An International Journal of Medicine*
527 103 (2010) 777–783.
- 528 [61] D. M. Wood, S. Davies, M. Puchnarewicz, J. Button, R. Archer,
529 H. Ovaska, J. Ramsey, T. Lee, D. W. Holt, P. I. Dargan, Recreational
530 use of mephedrone (4-methylmethcathinone, 4-mmC) with associated
531 sympathomimetic toxicity, *Journal of Medical Toxicology* 6 (2010)
532 327–330.
- 533 [62] D. Wood, S. Greene, P. Dargan, Clinical pattern of toxicity associated
534 with the novel synthetic cathinone mephedrone, *Emergency medicine
535 journal* 28 (2011) 280–282.
- 536 [63] P. I. Dargan, R. Sedefov, A. Gallegos, D. M. Wood, The phar-
537 macology and toxicology of the synthetic cathinone mephedrone (4-
538 methylmethcathinone), *Drug testing and analysis* 3 (2011) 454–463.
- 539 [64] D. Wood, P. Dargan, Understanding how data triangulation identifies
540 acute toxicity of novel psychoactive drugs, *Journal of Medical Toxicol-
541 ogy* 8 (2012) 300–303.
- 542 [65] B. Loi, J. M. Corkery, H. Claridge, C. Goodair, S. Chiappini, C. Gi-
543 meno Clemente, F. Schifano, Deaths of individuals aged 16–24 years in
544 the uk after using mephedrone, *Human Psychopharmacology: Clinical
545 and Experimental* 30 (2015) 225–232.

- 546 [66] P. Deluca, Z. Davey, O. Corazza, L. Di Furia, M. Farre, L. H. Flesland,
547 M. Mannonen, A. Majava, T. Peltoniemi, M. Pasinetti, et al., Identifying emerging trends in recreational drug use; outcomes from the psychonaut web mapping project, *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 39 (2012) 221–226.
- 551 [67] E. Cinosi, G. Martinotti, P. Simonato, D. Singh, Z. Demetrovics,
552 A. Roman-Urrestarazu, F. S. Bersani, B. Vicknasingam, G. Piazzon,
553 J.-H. Li, et al., Following “the roots” of kratom (*mitragyna speciosa*):
554 the evolution of an enhancer from a traditional use to increase work
555 and productivity in southeast asia to a recreational psychoactive drug
556 in western countries, *BioMed research international* 2015 (2015).
- 557 [68] O. Corazza, G. Valeriani, F. S. Bersani, J. Corkery, G. Martinotti,
558 G. Bersani, F. Schifano, “spice,” “kryptonite,” “black mamba”: an
559 overview of brand names and marketing strategies of novel psychoactive
560 substances on the web, *Journal of Psychoactive Drugs* 46 (2014)
561 287–294.
- 562 [69] O. Corazza, S. Assi, P. Simonato, J. Corkery, F. S. Bersani, Z. Demetrovics,
563 J. Stair, S. Fergus, C. Pezzolesi, M. Pasinetti, et al., Promoting
564 innovation and excellence to face the rapid diffusion of novel psychoactive
565 substances in the eu: the outcomes of the rednet project, *Human Psychopharmacology: Clinical and Experimental* 28 (2013) 317–323.
- 567 [70] F. Schifano, O. Corazza, P. Deluca, Z. Davey, L. Di Furia, M. Farre’,
568 L. Flesland, M. Mannonen, S. Pagani, T. Peltoniemi, et al., Psychoactive drug or mystical incense? overview of the online available
569 information on spice products, *International Journal of Culture and
570 Mental Health* 2 (2009) 137–144.
- 572 [71] O. Corazza, F. Schifano, P. Simonato, S. Fergus, S. Assi, J. Stair,
573 J. Corkery, G. Trincas, P. Deluca, Z. Davey, et al., Phenomenon of
574 new drugs on the internet: the case of ketamine derivative methoxetamine,
575 *Human Psychopharmacology: Clinical and Experimental* 27
576 (2012) 145–149.
- 577 [72] F. Schifano, P. Deluca, L. Agosti, G. Martinotti, J. M. Corkery, P. . R.
578 Group, New trends in the cyber and street market of recreational

- 579 drugs? the case of 2c-t-7 ('blue mystic'), *Journal of Psychopharmacol-*
580 *ogy* 19 (2005) 675–679.
- 581 [73] J. Welter, M. R. Meyer, P. Kavanagh, H. H. Maurer, Studies on the
582 metabolism and the detectability of 4-methyl-amphetamine and its iso-
583 mers 2-methyl-amphetamine and 3-methyl-amphetamine in rat urine
584 using gc-ms and lc-(high-resolution)-ms n, *Analytical and bioanalyti-*
585 *cal chemistry* 406 (2014) 1957–1974.
- 586 [74] J. Welter, P. Kavanagh, H. H. Maurer, Gc-ms and lc-(high-resolution)-
587 ms n studies on the metabolic fate and detectability of amphetamine
588 in rat urine, *Analytical and bioanalytical chemistry* 406 (2014) 3815–
589 3829.
- 590 [75] M. R. Meyer, F. T. Peters, H. H. Maurer, Automated mass spectral
591 deconvolution and identification system for gc-ms screening for drugs,
592 poisons, and metabolites in urine, *Clinical chemistry* 56 (2010) 575–
593 584.
- 594 [76] A. H. Ewald, D. Ehlers, H. H. Maurer, Metabolism and toxicological
595 detection of the designer drug 4-chloro-2, 5-dimethoxyamphetamine in
596 rat urine using gas chromatography-mass spectrometry, *Analytical and*
597 *bioanalytical chemistry* 390 (2008) 1837–1842.
- 598 [77] M. R. Meyer, M. Bach, J. Welter, M. Bovens, A. Turcant, H. H. Maurer,
599 Ketamine-derived designer drug methoxetamine: metabolism including
600 isoenzyme kinetics and toxicological detectability using gc-ms and lc-
601 (hr-) ms n, *Analytical and bioanalytical chemistry* 405 (2013) 6307–
602 6321.
- 603 [78] D. K. Wissenbach, M. R. Meyer, D. Remane, A. A. Weber, H. H.
604 Maurer, Development of the first metabolite-based lc-ms n urine drug
605 screening procedure-exemplified for antidepressants, *Analytical and*
606 *bioanalytical chemistry* 400 (2011) 79–88.
- 607 [79] D. K. Wissenbach, M. R. Meyer, D. Remane, A. A. Philipp, A. A.
608 Weber, H. H. Maurer, Drugs of abuse screening in urine as part of a
609 metabolite-based lc-msn screening concept, *Analytical and Bioanalyti-*
610 *cal Chemistry* 400 (2011) 3481–3489.

- 611 [80] J. B. Zawilska, D. Andrzejczak, Next generation of novel psychoac-
612 tive substances on the horizon—a complex problem to face, *Drug and*
613 *Alcohol Dependence* 157 (2015) 1–17.
- 614 [81] E. Papaseit, J. Moltó, R. Muga, M. Torrens, R. d. l. Torre, M. Farré,
615 Clinical pharmacology of the synthetic cathinone mephedrone, *Neu-*
616 *ropharmacology of New Psychoactive Substances (NPS)* (2016) 313–
617 331.
- 618 [82] C. Miliano, G. Serpelloni, C. Rimondo, M. Mereu, M. Marti, M. A.
619 De Luca, Neuropharmacology of new psychoactive substances (nps):
620 focus on the rewarding and reinforcing properties of cannabimimetics
621 and amphetamine-like stimulants, *Frontiers in neuroscience* 10 (2016)
622 153.
- 623 [83] K. N. Ellefsen, M. Concheiro, M. A. Huestis, Synthetic cathinone
624 pharmacokinetics, analytical methods, and toxicological findings from
625 human performance and postmortem cases, *Drug metabolism reviews*
626 48 (2016) 237–265.
- 627 [84] E. Papaseit, C. Pérez-Mañá, J.-A. Mateus, M. Pujadas, F. Fonseca,
628 M. Torrens, E. Olesti, R. De La Torre, M. Farré, Human pharmacology
629 of mephedrone in comparison with mdma, *Neuropsychopharmacology*
630 41 (2016) 2704–2713.
- 631 [85] C. Lovett, D. Wood, P. Dargan, Pharmacology and toxicology of the
632 synthetic cannabinoid receptor agonists, *Réanimation* 24 (2015) 527–
633 541.
- 634 [86] C. Kyriakou, E. Marinelli, P. Frati, A. Santurro, M. Afxentiou, S. Za-
635 ami, F. P. Busardo, Nbome: new potent hallucinogens—pharmacology,
636 analytical methods, toxicities, fatalities: a review, *Eur Rev Med Phar-*
637 *macol Sci* 19 (2015) 3270–3281.
- 638 [87] J. J. Nugteren-van Lonkhuyzen, A. J. van Riel, T. M. Brunt, L. Hon-
639 debrink, Pharmacokinetics, pharmacodynamics and toxicology of new
640 psychoactive substances (nps): 2c-b, 4-fluoroamphetamine and benzo-
641 furans, *Drug and alcohol dependence* 157 (2015) 18–27.

- 642 [88] M. Coppola, R. Mondola, 3, 4-methylenedioxypropylvalerone (mdpv):
643 chemistry, pharmacology and toxicology of a new designer drug of abuse
644 marketed online, *Toxicology Letters* 208 (2012) 12–15.
- 645 [89] S. L. Hill, T. Doris, S. Gurung, S. Katebe, A. Lomas, M. Dunn,
646 P. Blain, S. H. Thomas, Severe clinical toxicity associated with ana-
647 lytically confirmed recreational use of 25i-nbome: case series, *Clinical*
648 *Toxicology* 51 (2013) 487–492.
- 649 [90] D. James, R. D. Adams, R. Spears, G. Cooper, D. Lupton, J. P.
650 Thompson, S. H. Thomas, Clinical characteristics of mephedrone toxic-
651 ity reported to the uk national poisons information service, *Emergency*
652 *Medicine Journal* 28 (2011) 686–689.
- 653 [91] L. Karila, B. Megarbane, O. Cottencin, M. Lejoyeux, Synthetic cathi-
654 nones: a new public health problem, *Current neuropharmacology* 13
655 (2015) 12–20.
- 656 [92] H. A. Spiller, M. L. Ryan, R. G. Weston, J. Jansen, Clinical ex-
657 perience with and analytical confirmation of “bath salts” and “legal
658 highs” (synthetic cathinones) in the united states, *Clinical toxicology*
659 49 (2011) 499–505.
- 660 [93] D. Papanti, F. Schifano, G. Botteon, F. Bertossi, J. Mannix, D. Vidoni,
661 M. Impagnatiello, E. Pascolo-Fabrici, T. Bonavigo, “spicephrenia”: a
662 systematic overview of “spice”-related psychopathological issues and a
663 case report, *Human Psychopharmacology: Clinical and Experimental*
664 28 (2013) 379–389.
- 665 [94] F. Schifano, L. Orsolini, G. Duccio Papanti, J. M. Corkery, Novel
666 psychoactive substances of interest for psychiatry, *World Psychiatry*
667 14 (2015) 15–26.
- 668 [95] A. Salomone, Detection of new psychoactive substances, in: *Hair*
669 *Analysis in Clinical and Forensic Toxicology*, Elsevier, 2015, pp. 301–
670 336.
- 671 [96] M. S. Castaneto, A. Wohlfarth, N. A. Desrosiers, R. L. Hartman, D. A.
672 Gorelick, M. A. Huestis, Synthetic cannabinoids pharmacokinetics and
673 detection methods in biological matrices, *Drug metabolism reviews* 47
674 (2015) 124–174.

- 675 [97] R. Kronstrand, D. Guerrieri, S. Vikingsson, A. Wohlfarth, H. Gréen,
676 Fatal poisonings associated with new psychoactive substances, in: *New*
677 *psychoactive substances*, Springer, 2018, pp. 495–541.
- 678 [98] S. L. Hill, P. I. Dargan, Patterns of acute toxicity associated with new
679 psychoactive substances, in: *New Psychoactive Substances*, Springer,
680 2018, pp. 475–494.
- 681 [99] L. Ventura, F. Carvalho, R. J. Dinis-Oliveira, Opioids in the frame of
682 new psychoactive substances network: a complex pharmacological and
683 toxicological issue, *Current Molecular Pharmacology* 11 (2018) 97–108.
- 684 [100] M. H. Tang, Y. Chong, C. Y. Chan, C. Ching, C. Lai, Y. Li, T. W.
685 Mak, Cluster of acute poisonings associated with an emerging ketamine
686 analogue, 2-oxo-pce, *Forensic science international* 290 (2018) 238–243.
- 687 [101] C. R. Caffrey, P. M. Lank, When good times go bad: managing ‘legal
688 high’ complications in the emergency department, *Open access emer-*
689 *gency medicine: OAEM* 10 (2018) 9.
- 690 [102] M. Bäckberg, O. Beck, A. Helander, Phencyclidine analog use in swe-
691 den—intoxication cases involving 3-meo-pcp and 4-meo-pcp from the
692 strida project, *Clinical Toxicology* 53 (2015) 856–864.
- 693 [103] M. Bäckberg, O. Beck, K.-H. Jönsson, A. Helander, Opioid intoxica-
694 tions involving butyrfentanyl, 4-fluorobutyrfentanyl, and fentanyl from
695 the swedish strida project, *Clinical Toxicology* 53 (2015) 609–617.
- 696 [104] A. Helander, O. Beck, M. Bäckberg, Intoxications by the dissociative
697 new psychoactive substances diphenidine and methoxphenidine, *Clin-*
698 *ical toxicology* 53 (2015) 446–453.
- 699 [105] A. Helander, M. Bäckberg, Epidemiology of nps based confirmed over-
700 dose cases: the strida project, in: *New Psychoactive Substances*,
701 Springer, 2018, pp. 461–473.
- 702 [106] M. Bäckberg, K.-H. Jönsson, O. Beck, A. Helander, Investigation of
703 drug products received for analysis in the swedish strida project on new
704 psychoactive substances, *Drug testing and analysis* 10 (2018) 340–349.

- 705 [107] O. Beck, L. Franzen, M. Bäckberg, P. Signell, A. Helander, Intoxi-
706 cations involving mdpv in sweden during 2010–2014: results from the
707 strida project, *Clinical toxicology* 53 (2015) 865–873.
- 708 [108] K. Miotto, J. Striebel, A. K. Cho, C. Wang, Clinical and pharmacolog-
709 ical aspects of bath salt use: a review of the literature and case reports,
710 *Drug and alcohol dependence* 132 (2013) 1–12.
- 711 [109] I. M. McIntyre, R. D. Gary, S. Joseph, R. Stabley, A fatality related to
712 the synthetic opioid u-47700: postmortem concentration distribution,
713 *Journal of Analytical Toxicology* 41 (2017) 158–160.
- 714 [110] A. Helander, M. Bäckberg, O. Beck, Intoxications involving the fen-
715 tanyl analogs acetylfentanyl, 4-methoxybutyrfentanyl and furanylfen-
716 tanyl: results from the swedish strida project, *Clinical Toxicology* 54
717 (2016) 324–332.
- 718 [111] M. Bäckberg, L. Tworek, O. Beck, A. Helander, Analytically confirmed
719 intoxications involving mdmb-chmica from the strida project, *Journal*
720 *of medical toxicology* 13 (2017) 52–60.
- 721 [112] B. K. Logan, A. L. Mohr, M. Friscia, A. J. Krotulski, D. M. Papsun,
722 S. L. Kacinko, J. D. Roper-Miller, M. A. Huestis, Reports of adverse
723 events associated with use of novel psychoactive substances, 2013–2016:
724 a review, *Journal of Analytical Toxicology* 41 (2017) 573–610.
- 725 [113] P. Adamowicz, D. Zuba, Fatal intoxication with methoxetamine, *Jour-*
726 *nal of Forensic Sciences* 60 (2015) S264–S268.
- 727 [114] M. Bäckberg, O. Beck, P. Hulten, J. Rosengren-Holmberg, A. Helander,
728 Intoxications of the new psychoactive substance 5-(2-aminopropyl) in-
729 dole (5-it): a case series from the swedish strida project, *Clinical*
730 *toxicology* 52 (2014) 618–624.
- 731 [115] R. Kronstrand, G. Thelander, D. Lindstedt, M. Roman, F. Kugelberg,
732 Fatal intoxications associated with the designer opioid ah-7921, *Journal*
733 *of analytical toxicology* 38 (2014) 599–604.
- 734 [116] A. Cannaeert, E. Sparkes, E. Pike, J. L. Luo, A. Fang, R. C. Kevin,
735 R. Ellison, R. Gerona, S. D. Banister, C. P. Stove, Synthesis and

- 736 in vitro cannabinoid receptor 1 activity of recently detected syn-
737 thetic cannabinoids 4f-mdmb-bica, 5f-mpp-pica, mmb-4en-pica, cumyl-
738 cbmica, adb-binaca, app-binaca, 4f-mdmb-binaca, mdmb-4en-pinaca,
739 a-chminaca, 5f-ab-p7aica, 5f-mdmb-p7aica, and 5f-ap7aica, ACS
740 Chemical Neuroscience 11 (2020) 4434–4446.
- 741 [117] A. Ametovski, C. Macdonald, J. J. Manning, S. S. Haneef, M. San-
742 tiago, L. Martin, E. Sparkes, A. Reckers, R. R. Gerona, M. Connor,
743 et al., Exploring stereochemical and conformational requirements at
744 cannabinoid receptors for synthetic cannabinoids related to sdb-006, 5f-
745 sdb-006, cumyl-pica, and 5f-cumyl-pica, ACS Chemical Neuroscience
746 11 (2020) 3672–3682.
- 747 [118] V. Shevyrin, V. Melkozerov, G. W. Endres, Y. Shafran, Y. Morzherin,
748 On a new cannabinoid classification system: a sight on the illegal mar-
749 ket of novel psychoactive substances, Cannabis and Cannabinoid Re-
750 search 1 (2016) 186–194.
- 751 [119] N. I. o. D. A. N. I. o. H. U. D. o. H. , H. Services, Cannabis (mari-
752 juana) drugfacts, 2022. URL: [https://nida.nih.gov/publications/
753 drugfacts/cannabis-marijuana#ref](https://nida.nih.gov/publications/drugfacts/cannabis-marijuana#ref).
- 754 [120] E. Y. Chung, H. J. Cha, H. K. Min, J. Yun, Pharmacology and adverse
755 effects of new psychoactive substances: synthetic cannabinoid receptor
756 agonists, Archives of Pharmacal Research 44 (2021) 402–413.
- 757 [121] S. Sachdev, S. D. Banister, M. Santiago, C. Bladen, M. Kassiou,
758 M. Connor, Differential activation of g protein-mediated signaling by
759 synthetic cannabinoid receptor agonists, Pharmacology research & per-
760 spectives 8 (2020) e00566.
- 761 [122] M. Patel, J. J. Manning, D. B. Finlay, J. A. Javitch, S. D. Banister,
762 N. L. Grimsey, M. Glass, Signalling profiles of a structurally diverse
763 panel of synthetic cannabinoid receptor agonists, Biochemical Phar-
764 macology 175 (2020) 113871.
- 765 [123] Z. Hassan, O. G. Bosch, D. Singh, S. Narayanan, B. V. Kasinather,
766 E. Seifritz, J. Kornhuber, B. B. Quednow, C. P. Müller, Novel psy-
767 choactive substances—recent progress on neuropharmacological mech-
768 anisms of action for selected drugs, Frontiers in psychiatry 8 (2017)
769 152.

- 770 [124] H. Chung, J. Lee, E. Kim, Trends of novel psychoactive substances
771 (npss) and their fatal cases, *Forensic Toxicology* 34 (2016) 1–11.
- 772 [125] V. L. Alves, J. L. Gonçalves, J. Aguiar, H. M. Teixeira, J. S. Câmara,
773 The synthetic cannabinoids phenomenon: from structure to toxicolog-
774 ical properties. a review, *Critical Reviews in Toxicology* 50 (2020)
775 359–382.
- 776 [126] A. Giorgetti, F. P. Busardò, R. Tittarelli, V. Auwärter, R. Giorgetti,
777 Post-mortem toxicology: a systematic review of death cases involving
778 synthetic cannabinoid receptor agonists, *Frontiers in Psychiatry* 11
779 (2020) 464.
- 780 [127] T. Coccini, U. De Simone, D. Lonati, G. Scaravaggi, M. Marti, C. Lo-
781 catelli, Mam-2201, one of the most potent—naphthoyl indole deriva-
782 tive—synthetic cannabinoids, exerts toxic effects on human cell-based
783 models of neurons and astrocytes, *Neurotoxicity Research* 39 (2021)
784 1251–1273.
- 785 [128] M. Valento, J. Lebin, Emerging drugs of abuse: synthetic cannabinoids,
786 phenylethylamines (2c drugs), and synthetic cathinones, *Clinical Pe-
787 diatric Emergency Medicine* 18 (2017) 203–211.
- 788 [129] R. Kikura-Hanajiri, New designer drugs in japan, in: *Neuropathology
789 of drug addictions and substance misuse*, Elsevier, 2016, pp. 1055–1065.
- 790 [130] J. Trecki, R. R. Gerona, M. D. Schwartz, et al., Synthetic cannabinoid-
791 related illnesses and deaths, *N Engl J Med* 373 (2015) 103–107.
- 792 [131] S. D. Banister, M. Longworth, R. Kevin, S. Sachdev, M. Santiago,
793 J. Stuart, J. B. Mack, M. Glass, I. S. McGregor, M. Connor, et al.,
794 Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5f-
795 ambica, 5f-amb, 5f-adb, amb-fubinaca, mdmb-fubinaca, mdmb-chmica,
796 and their analogues, *ACS Chemical Neuroscience* 7 (2016) 1241–1254.
- 797 [132] C. Hess, C. T. Schoeder, T. Pillaiyar, B. Madea, C. E. Müller, Pharma-
798 cological evaluation of synthetic cannabinoids identified as constituents
799 of spice, *Forensic toxicology* 34 (2016) 329–343.

- 800 [133] D. Rudin, M. E. Liechti, D. Luethi, Molecular and clinical aspects
801 of potential neurotoxicity induced by new psychoactive stimulants and
802 psychedelics, *Experimental neurology* 343 (2021) 113778.
- 803 [134] S. Elliott, J. Evans, A 3-year review of new psychoactive substances in
804 casework, *Forensic science international* 243 (2014) 55–60.
- 805 [135] S. Zaami, R. Giorgetti, S. Pichini, F. Pantano, E. Marinelli, F. Busardò,
806 Synthetic cathinones related fatalities: an update, *Eur Rev Med Phar-*
807 *macol Sci* 22 (2018) 268–274.
- 808 [136] L. Hondebrink, A. Zwartsen, R. H. Westerink, Effect fingerprinting of
809 new psychoactive substances (nps): What can we learn from in vitro
810 data?, *Pharmacology & therapeutics* 182 (2018) 193–224.
- 811 [137] A. Rickli, D. Luethi, J. Reinisch, D. Buchy, M. C. Hoener, M. E.
812 Liechti, Receptor interaction profiles of novel n-2-methoxybenzyl
813 (nbome) derivatives of 2, 5-dimethoxy-substituted phenethylamines (2c
814 drugs), *Neuropharmacology* 99 (2015) 546–553.
- 815 [138] A. J. Eshleman, K. M. Wolfrum, J. F. Reed, S. O. Kim, R. A. Johnson,
816 A. Janowsky, Neurochemical pharmacology of psychoactive substituted
817 n-benzylphenethylamines: High potency agonists at 5-HT_{2A} receptors,
818 *Biochemical pharmacology* 158 (2018) 27–34.
- 819 [139] L. Simmler, A. Rickli, M. Hoener, M. Liechti, Monoamine transporter
820 and receptor interaction profiles of a new series of designer cathinones,
821 *Neuropharmacology* 79 (2014) 152–160.
- 822 [140] M. M. Vandeputte, N. Verougstraete, D. Walther, G. C. Glatfelter,
823 J. Malfliet, M. H. Baumann, A. G. Verstraete, C. P. Stove, First
824 identification, chemical analysis and pharmacological characterization
825 of n-piperidinyl etonitazene (etonitazepipne), a recent addition to the 2-
826 benzylbenzimidazole opioid subclass, *Archives of Toxicology* 96 (2022)
827 1865–1880.
- 828 [141] M. M. Vandeputte, M. Persson, D. Walther, S. Vikingsson, R. Kro-
829 nstrand, M. H. Baumann, H. Gréen, C. P. Stove, Characterization
830 of recent non-fentanyl synthetic opioids via three different in vitro μ -
831 opioid receptor activation assays, *Archives of Toxicology* 96 (2022)
832 877–897.

- 833 [142] S. Salle, S. Bodeau, A. Dhersin, M. Ferdonnet, R. Goncalves,
834 M. Lenski, B. Lima, M. Martin, J. Outreville, J. Vaucel, et al., Novel
835 synthetic opioids: A review of the literature, *Toxicologie Analytique*
836 *et Clinique* 31 (2019) 298–316.
- 837 [143] N. C. f. H. S. CDC, U.s. overdose deaths in 2021 increased half as much
838 as in 2020 - but are still up 15%, 2022. URL: [https://www.cdc.gov/
839 nchs/pressroom/nchs_press_releases/2022/202205.htm](https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm).
- 840 [144] C. for Disease Control, Prevention, Understanding the epidemic, 2021.
841 URL: <https://www.cdc.gov/drugoverdose/epidemic/index.html>.
- 842 [145] C. L. Mattson, L. J. Tanz, K. Quinn, M. Kariisa, P. Patel, N. L. Davis,
843 Trends and geographic patterns in drug and synthetic opioid overdose
844 deaths—united states, 2013–2019, *Morbidity and Mortality Weekly*
845 *Report* 70 (2021) 202.
- 846 [146] M. P. Prekupec, P. A. Mansky, M. H. Baumann, Misuse of novel
847 synthetic opioids: a deadly new trend, *Journal of addiction medicine*
848 11 (2017) 256.
- 849 [147] M. H. Baumann, S. Majumdar, V. Le Rouzic, A. Hunkele, R. Uprety,
850 X. P. Huang, J. Xu, B. L. Roth, Y.-X. Pan, G. W. Pasternak, Pharma-
851 cological characterization of novel synthetic opioids (nso) found in the
852 recreational drug marketplace, *Neuropharmacology* 134 (2018) 101–
853 107.
- 854 [148] I. Tabarra, S. Soares, T. Rosado, J. Gonçalves, Â. Luís, S. Malaca,
855 M. Barroso, T. Keller, J. Restolho, E. Gallardo, Novel synthetic
856 opioids—toxicological aspects and analysis, *Forensic Sciences Research*
857 4 (2019) 111–140.
- 858 [149] N. Allibe, F. Billault, C. Moreau, A. Marchard, Y. Gaillard, G. Hoizey,
859 H. Eysseric-Guerin, N. Milan, Ocfentanil in france: seven case reports
860 (2016–2018), *Toxicologie Analytique et Clinique* 31 (2019) 317–322.
- 861 [150] S. Darke, A. Peacock, J. Duflou, M. Farrell, J. Lappin, Characteristics
862 of fatal ‘novel’synthetic opioid toxicity in australia, *Drug and alcohol*
863 *dependence* 232 (2022) 109292.

- 864 [151] L. Karila, M. Marillier, B. Chaumette, J. Billieux, N. Franchitto,
865 A. Benyamina, New synthetic opioids: Part of a new addiction land-
866 scape, *Neuroscience & Biobehavioral Reviews* 106 (2019) 133–140.
- 867 [152] B. Lovrecic, M. Lovrecic, B. Gabrovec, M. Carli, M. Pacini, A. G.
868 Maremmani, I. Maremmani, Non-medical use of novel synthetic opi-
869 oids: a new challenge to public health, *International journal of envi-
870 ronmental research and public health* 16 (2019) 177.
- 871 [153] A. Y. Simão, M. Antunes, E. Cabral, P. Oliveira, L. M. Rosendo, A. T.
872 Brinca, E. Alves, H. Marques, T. Rosado, L. A. Passarinha, et al.,
873 An update on the implications of new psychoactive substances in pub-
874 lic health, *International journal of environmental research and public
875 health* 19 (2022) 4869.